Need Help?
No Article Versions Notes Found
Cite
Thokagevistk, K.; François, C.; Brignone, M.; Toumi, M. From Investigational Product to Active Reference: Evolution of Oral Aumatriptan Efficacy versus Placebo for the Treatment of Acute Migraine Episodes and Potential Impact in Comparative Analyses. J. Mark. Access Health Policy 2019, 7, 1603538. https://doi.org/10.1080/20016689.2019.1603538
Thokagevistk K, François C, Brignone M, Toumi M. From Investigational Product to Active Reference: Evolution of Oral Aumatriptan Efficacy versus Placebo for the Treatment of Acute Migraine Episodes and Potential Impact in Comparative Analyses. Journal of Market Access & Health Policy. 2019; 7(1):1603538. https://doi.org/10.1080/20016689.2019.1603538
Chicago/Turabian StyleThokagevistk, Katia, Clément François, Mélanie Brignone, and Mondher Toumi. 2019. "From Investigational Product to Active Reference: Evolution of Oral Aumatriptan Efficacy versus Placebo for the Treatment of Acute Migraine Episodes and Potential Impact in Comparative Analyses" Journal of Market Access & Health Policy 7, no. 1: 1603538. https://doi.org/10.1080/20016689.2019.1603538
APA StyleThokagevistk, K., François, C., Brignone, M., & Toumi, M. (2019). From Investigational Product to Active Reference: Evolution of Oral Aumatriptan Efficacy versus Placebo for the Treatment of Acute Migraine Episodes and Potential Impact in Comparative Analyses. Journal of Market Access & Health Policy, 7(1), 1603538. https://doi.org/10.1080/20016689.2019.1603538
